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Objective: To increase response rates to therapy by increasing the dosage of proton pump 
inhibitor (PPI) therapy in patients with gastroesophageal reflux disease (GERD) whose   symptoms 
are predominantly associated with acid reflux.
Methods: In this double-blind, randomized, proof-of-concept study, 369 patients with GERD 
and moderate heartburn lasting $three days/week, a history of response to antacids/acid 
suppression therapy, and a positive esophageal acid perfusion test result were randomized 
to esomeprazole 20 or 40 mg once daily, or to 40 mg twice daily for four weeks. Heartburn 
symptom relief/resolution was subsequently evaluated.
Results: In this study population, no relationship was apparent between esomeprazole dosage 
and efficacy variables for sustained heartburn resolution (seven days without symptoms) at 
week 4 (48.0%, 44.0%, and 41.4% for esomeprazole 20 mg once daily, 40 mg once daily, and 
40 mg twice daily, respectively). Nocturnal heartburn resolution with esomeprazole 40 mg twice 
daily showed a numeric improvement trend versus esomeprazole 20 and 40 mg once daily, but 
this was not statistically significant.
Conclusions: Heartburn resolution rates at four weeks were similar for all esomeprazole dosages 
and comparable with rates reported previously, suggesting a plateau effect in terms of clinical 
response to acid suppression with PPI therapy in this population of selected GERD patients.
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Introduction
Gastroesophageal reflux disease (GERD) manifests as heartburn and/or acid regur-
gitation at least once weekly, and occurs in 10% to 20% of people in the Western 
world.1 Several approaches can be used to evaluate a patient for GERD. A diagnosis of 
GERD can be assumed in patients with classic symptoms who respond to appropriate 
antacid therapy,2,3 but not all patients with GERD respond to standard treatment.3,4 
A pooled meta-analysis of 15 studies showed that symptom resolution with proton 
pump   inhibitors (PPIs) has a sensitivity of 78% and a specificity of 54% for GERD, as 
determined by 24-hour pH monitoring.4 Additionally, the esophageal acid perfusion test 
result,5 which presumptively links clinical symptoms to esophageal acid exposure when 
elicited by acid infusion, demonstrates a clinical correlation with GERD symptoms.6,7 
However, a lack of association exists between esophageal acid perfusion-induced 
symptoms and symptoms that follow spontaneous reflux in the same individuals.8
PPIs are recommended as first-line therapy for GERD9 when acid suppression is 
required because they provide rapid symptomatic relief of GERD and more frequently 
heal esophagitis than other classes of acid suppressants.3 However, studies suggest 
that 30% of patients with GERD still experience symptoms despite standard treatment Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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with a PPI.10 Inadequate control of gastric acid secretion may 
be one explanation for the persistence of GERD symptoms 
in these patients,11 and an alteration in the dosing regimen 
may be warranted to optimize the PPI effect. In patients who 
do not respond to once-daily dosing, expert opinion recom-
mends an increase in dosage to twice daily for symptom 
relief, even though supporting clinical data are limited.9 In 
a study of patients with Barrett’s esophagus, esomeprazole 
40 mg twice daily, 40 mg three times daily, and 20 mg three 
times daily, yielded significantly improved, dose-dependent 
intragastric pH values without a comparable effect on 
esophageal pH values.12 Alternative regimens designed to 
optimize the effectiveness of PPI therapy include split-dose 
regimens,13 increased doses,14 and alternative timing of dose 
administration.15–18
Due to the variety of pathophysiologic mechanisms that 
may result in heartburn or other esophageal symptoms, treat-
ment with a PPI may not provide complete symptom resolution. 
Some patients may fail to respond optimally to PPIs because 
of differences in disease or patient clinical characteristics or 
because they lack “true” acid-induced, GERD-associated 
heartburn.19–21 Patients with nonerosive reflux disease are 
reported to have a lower symptom response rate than those with 
erosive esophagitis.19 Furthermore, patients may be treated 
with a PPI without having acid-induced, GERD-associated 
heartburn because they misunderstand the meaning of heart-
burn and use the term to describe   epigastric pain.21
If heartburn symptoms could be objectively characterized 
as acid-associated, the subset of patients who would most 
benefit from acid suppression therapy could be identified 
with the objective of possibly increasing their symptomatic 
response with increased dosages. Therefore, the aim of this 
proof-of-concept study was to investigate the relationship 
between esomeprazole dose and symptom resolution in 
patients with GERD-associated heartburn, as determined by 
a history of response to antacids or acid suppression therapy 
and a positive esophageal acid perfusion test result.
Methods
Patients
Adults aged 18–75 years were eligible for study entry if 
they had a history of heartburn for $six months and a prior 
self-reported symptomatic response to antacids and/or acid 
suppression therapy, although the time to response to antacid 
or acid suppression therapy was not determined. Women 
had to be postmenopausal, surgically sterilized, or using an 
acceptable form of birth control during the study. Patients 
were required to have a positive result on esophageal acid 
perfusion test, and had to test negative for Helicobacter pylori 
infection (determined by a whole blood H. pylori test), and 
had to be able to use an electronic diary (e-diary).
Exclusion criteria included a history of gastric or esopha-
geal surgery (except for closure of perforated peptic ulcer), 
a history of endoscopically verified erosive esophagitis within 
the last 16 weeks (unless healing was documented), current 
high-dose (more than standard approved) PPI treatment, 
evidence of other major gastrointestinal, cardiovascular, 
cerebrovascular, pulmonary, renal, pancreatic, or liver disease, 
malignant disease, or solid organ transplant. Patients were 
also excluded from the study if they required concomitant 
therapies, including acid suppression therapy (histamine-2 
receptor antagonists or PPIs other than study drug), sucralfate, 
promotility drugs, benzodiazepines, anticoagulants, anticholin-
ergics, analgesics, prostaglandin analogs, antineoplastic drugs, 
acetylsalicylic acid (except at a dosage of #165 mg/day for 
cardiovascular disease prophylaxis), corticosteroids, gastroin-
testinal/esophageal irritants, drugs requiring gastric acid for 
optimal absorption, narcotics, or human immunodeficiency 
virus protease inhibitors. The use of any other investigational 
drug within 28 days of randomization was also prohibited.
study design
This randomized, parallel-group, double-blind, multicenter, 
proof-of-concept study (AstraZeneca study code D9612 
L00064; ClinicalTrials.gov identifier, NCT00206024) was 
conducted at 25 US centers (predominantly   gastroenterology 
practices) between November 2004 and July 2005. The study 
was performed in accordance with the ethical principles 
of the Declaration of Helsinki and its amendments,22 and 
was in compliance with the International Conference on 
  Harmonization/Good Clinical Practice regulations.23 Patients 
provided written informed consent before the initiation of 
any study procedure.
At the initial screening visit, physical examination results, 
demographic and baseline disease characteristics, and medical 
histories were obtained. Eligible patients entered a two-week 
runin period during which they reported daily heartburn 
symptoms via e-diaries (handheld PHT LogPad; PHT Cor-
poration, Charlestown, MA). Patients could use antacid tablets 
(Gelusil; Wellspring Pharmaceutical Corporation, Sarasota, 
FL) as rescue medication for up to three   consecutive days per 
week during the runin period. At the end of this period, patients 
who reported heartburn of at least moderate severity (discom-
forting symptom sufficient to cause   interference with normal 
activities, including sleep) on $three of the previous seven 
days in their e-diary and who had not used acid   suppression Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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therapy (eg, PPIs or histamine-2 receptor antagonists) other 
than the rescue medication (Gelusil tablets) underwent an 
esophageal acid perfusion test.
The esophageal acid perfusion test was performed on 
day 0, using a technique based on the Bernstein test with some 
modifications.5 The patient was placed in an upright   position, 
and a lubricated, small-bore (#12-French) catheter was passed 
transnasally and placed in the distal esophagus, which had been 
located by esophageal manometry or a pH step-up procedure. 
The test included a five-minute infusion of normal saline 
at a rate of 1.5 mL/min and a subsequent infusion of 0.1 N 
hydrochloric acid at a rate of 1.5 mL/min, and lasting until 
symptoms appeared or 30 minutes had elapsed. The patient 
was instructed to indicate whether typical heartburn symptoms 
occurred during infusions, but the patient was unaware of the 
content of the infusion. The test result was considered positive 
only if symptoms were reported during the acid infusion.
Assignment
Patients who had moderate heartburn and a positive esopha-
geal acid perfusion test result were assigned randomly (1:1:1) 
in a double-blind, double-dummy fashion to four weeks of 
treatment with esomeprazole magnesium 20 mg once daily, 
40 mg once daily, or 40 mg twice daily. The patients were 
instructed to take their treatment 30 minutes before their 
morning and evening meals. During the four weeks of treat-
ment, patients assessed their heartburn symptoms before 
each morning dose of study medication and recorded their 
assessments via e-diaries.
Masking
Randomized patients received one capsule in the morning 
and one capsule in the evening, regardless of treatment, and 
esomeprazole magnesium and placebo capsules were   identical 
in appearance. Treatment codes indicating the treatment 
randomization for each randomized patient were   available 
to the investigators or pharmacists at the study center. The 
treatment code was not to be broken except in medical 
emergencies when the appropriate management of the patient 
necessitated knowledge of the treatment randomization. 
All personnel involved in the monitoring or the   analysis of 
the study remained blinded to the   allocation schedule until 
the study was completed, the data were screened, and any 
protocol violators were identified.
Assessments
At the screening visit, patients received an e-diary to record 
heartburn and nocturnal heartburn symptoms and instructions 
for its use. Heartburn was defined as a burning feeling rising 
from the stomach or lower part of the chest toward the neck. 
Nocturnal heartburn was defined as heartburn that occurred 
from the time the patient retired for the evening until the 
patient rose in the morning to start daily activities.
Using a severity scale (none = 0; mild = 1; moderate = 2; 
severe = 3),24–26 patients responded to the following statement 
on their handheld e-diary devices: “Please rate the severity 
of your most intense heartburn episode during the previous 
24 hours”. In response to the question, “Did you experience 
nocturnal heartburn during your normal sleeping hours?” 
patients also recorded the presence (no = 0; yes = 1) of 
  nocturnal heartburn during nighttime hours.
Efficacy measures assessed in each treatment group were 
sustained resolution of heartburn (defined as seven consecu-
tive days with a daily e-diary heartburn assessment of “none”) 
and relief of heartburn during week 4 of treatment and 
included all patients who had sustained resolution and those 
who experienced six consecutive days with a daily e-diary 
assessment of “none” and one day of “mild” (ie, all patients 
who had six days with a daily e-diary assessment of “none” 
and one day of “none” or “mild”). The cumulative daily sus-
tained resolution rate through 4 weeks of treatment also was 
assessed. The times to the first day of the sustained resolution 
of heartburn and to the first day of relief of heartburn were 
determined. The percentages of heartburn-free days and nights 
during week 4 of treatment were calculated.
Patients were required to bring unused rescue medica-
tion to the study site on the day of randomization (day 0) 
and unused study drug to the study site on the final visit. 
Returned tablets/capsules were counted and documented 
in the patient’s source documents and case report form. 
Investigators were responsible for ensuring that accurate 
accountability records were kept. Treatment compliance was 
assessed from reviewing accountability records, and patients 
were considered compliant if they consumed $80% of the 
prescribed study drug.
Safety and tolerability assessments were based on adverse 
event (AE) reports, laboratory data, vital signs, and   physical 
examination results. AEs were recorded at day 0 and at the 
end of the study in response to an open question by the 
investigator. Spontaneously reported AEs also were recorded 
throughout the study.
Statistical analysis
No hypothesis was made and no statistical comparisons or 
statistical inferences were drawn for this exploratory study. 
Sample sizes were based on those used in a previous study, Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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for which it was calculated that a sample size of 100 patients 
would have a 95% power to detect a difference in resolu-
tion rates of 60% for esomeprazole treatment and 30% for 
placebo treatment.24 Thus, allowing for a 10% dropout rate, 
330 patients had to be randomized to provide approximately 
100 patients per treatment arm. The efficacy variables were 
summarized in the intent-to-treat population, defined as all 
patients who took $one dose of study drug and had $one 
efficacy measurement. The safety population included all 
patients who took $one dose of study medication.
Results
Of 630 patients screened, 369 were randomly assigned to 
treatment. The major reasons for study exclusion and discon-
tinuation are summarized in Figure 1. All 369   randomized 
patients who reported that their heartburn responded to 
antacids/acid suppression therapy also had a positive esopha-
geal acid perfusion test result except for one. This patient 
died in a traffic accident and thus was not included in the 
intent-to-treat population (368 patients) because no data 
were recorded after the second visit (day 0). All randomized 
patients received $one dose of study drug; data from all 
randomized patients were analyzed for safety. Patients in this 
population had a mean age of 45 years, were predominantly 
white women, and had a mean body mass index of .29 kg/m2 
(Table 1). All patients had a history of heartburn, tested 
negative for H. pylori, and had a positive esophageal acid 
perfusion test result. Thirteen percent of patients had a 
history of erosive esophagitis. Prior to study enrollment, 
31 (8.4%) of the 368 patients were receiving histamine-2 
receptor antagonists and 114 (31.0%) were receiving PPI 
therapy, including 35 (9.5%) patients who were receiving 
esomeprazole. Most patients were classified as compliant (ie, 
took $80% of their study medication), including 112 (93%) 
in the 20-mg once-daily and 40-mg once-daily groups, and 
113 (90%) in the 40-mg twice-daily groups. No instances of 
treatment overdose were reported.
As shown in Table 2, no apparent relationship existed 
between the dosage of esomeprazole and any of the efficacy 
variables, including sustained resolution and relief rates at 
week 4, cumulative daily sustained resolution rate at day 28, 
time to first day of sustained resolution or relief, and   percentage 
of heartburn-free days during week 4. However, a nonsig-
nificant trend was seen toward improved nocturnal heartburn 
Screened
(N = 630)
Randomized
(N = 369)
Esomeprazole 20 mg
once daily
(n = 122)
Esomeprazole 40 mg
once daily
(n = 121)
Esomeprazole 40 mg
twice daily
(n = 126)
Lost to follow-up (n = 2)
Other (n = 1)
Completed
(n = 119; 98%)
Discontinued (n = 3)
Adverse event (n = 3)
Other (n = 5)
Completed
(n = 113; 93%)
Discontinued (n = 8)
Adverse event (n = 2)
Lost to follow-up (n = 1)
Other (n = 2)
Completed
(n = 121; 96%)
Discontinued (n = 5)
Screen failures (n = 261)
Failed e-dairy criteria (n = 111)
Withdrew consent (n = 40)
H. pylori-positive (n = 33)
Acid perfusion test negative or
not done (n = 19)
Lost to follow-up (n = 18)
Excluded medication (n = 14)
Other reason (n = 19)
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Table 2 Efficacy of esomeprazole 20 mg once daily, 40 mg once daily, or 40 mg twice daily in the treatment of acid-related 
heartburn
Efficacy variable Esomeprazole 20 mg  
once daily
Esomeprazole 40 mg  
once daily
Esomeprazole 40 mg   
twice daily
sustained hB resolution rate during week 4,a n/n (%) 47/98 (48.0) 40/91 (44.0) 41/99 (41.4)
hB relief rate during week 4,a n/n (%) 58/98 (59.2) 47/91 (51.7) 53/99 (53.5)
Cumulative daily sustained hB resolution rate at day 28, n/n (%) 27/43 (62.8) 26/50 (52.0) 31/50 (62.0)
Time to first day of first sustained HB resolution, n 121 121 126
  Mean (sEM), days 14.7 (1) 14.0 (1) 15.5 (1)
Time to first day of first HB relief, n 121 121 126
  Mean (sEM), days 12.1 (1) 12.5 (1) 12.9 (1)
HB-free days during week 4,a n 120 112 121
  Mean (sEM), % 66.5 (4) 62.4 (4) 67.8 (3)
HB-free nights during week 4,a n 120 112 121
  Mean (sEM), % 80.8 (3) 78.0 (3) 88.2 (2)
Notes: aLast observation carried forward was used in the analyses of sustained resolution and relief rates during week 4 for patients whose last diary data were from days 
26 or 27. This approach was necessary because of the limited number of patients with data for day 28. 
Abbreviations: hB, heartburn; sEM, standard error of the mean. 
Table 1 Demographic and baseline disease characteristics
Characteristic Esomeprazole 20 mg  
once daily 
(n = 121)
Esomeprazole 40 mg  
once daily 
(n = 121)
Esomeprazole 40 mg  
twice daily 
(n = 126)
Total 
(n = 368)
sex, n (%)
  Men 56 (46.3) 51 (42.1) 48 (38.1) 155 (42.1)
  Women 65 (53.7) 70 (57.9) 78 (61.9) 213 (57.9)
Age, years
  Mean (sD) 43.7 (13.5) 43.9 (12.1) 46.9 (13.2) 44.9 (13.0)
  range 19–72 21–71 20–74 19–74
race, n (%)
  White 71 (58.7) 72 (59.5) 73 (57.9) 216 (58.7)
  Black 7 (5.8) 10 (8.3) 13 (10.3) 30 (8.2)
  Asian 6 (5.0) 4 (3.3) 1 (0.8) 11 (3.0)
  Othera 37 (30.6) 35 (28.9) 39 (31.0) 111 (30.2)a
BMi, kg/m2
  Mean (sD) 29.2 (5.8) 29.8 (6.3) 30.5 (6.6) 29.8 (6.3)
  range 18–57 18–52 19–64 18–64
heartburn history, n (%)
  0.5–5 years 7 (5.8) 11 (9.1) 8 (6.3) 26 (7.1)
 . 5 years 114 (94.2) 110 (90.9) 118 (93.7) 342 (92.9)
Erosive esophagitis history, n (%)
  no 105 (86.8) 106 (87.6) 111 (88.1) 322 (87.5)
  Yes 16 (13.2) 15 (12.4) 15 (11.9) 46 (12.5)
Prior medications, n (%)
 h 2rA 6 (5.0) 12 (9.9) 13 (10.3) 31 (8.4)
  Any PPi 39 (32.2) 40 (33.1) 35 (27.8) 114 (31.0)
  Esomeprazole 10 (8.3) 13 (10.7) 12 (9.5) 35 (9.5)
Note: aApproximately 90% of patients in the “other” race category identified themselves as Hispanic. 
Abbreviations: BMi, body mass index; h2RA, histamine-2 receptor antagonist; PPI, proton pump inhibitor; SD, standard deviation.
resolution with esomeprazole 40 mg twice daily compared 
with esomeprazole 20 mg once daily and 40 mg once daily in 
terms of heartburn-free nights during week 4 (Table 2).
All three esomeprazole dosage regimens were well toler-
ated (Table 3). Three serious AEs were observed: pulmonary 
abscess, atypical chest pain, and death in a   traffic accident. 
However, none of these events were attributed to esomepra-
zole treatment. The incidence of AEs was slightly higher 
with esomeprazole 40 mg twice daily (21%) compared with 
esomeprazole 20 mg once daily (17%) and 40 mg once daily Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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(18%). Study medication was discontinued because of AEs 
in three patients who received   esomeprazole 40 mg once 
daily: one patient with severe symptoms of fatigue, arthralgia, 
myalgia, hyperhidrosis, and blurred vision; one patient with 
mild nausea and diarrhea; and one patient with moderate 
diarrhea. Two patients who received esomeprazole 40 mg 
twice daily also discontinued study medication; one of these 
patients discontinued due to moderate noncardiac chest pain 
and one due to severe injury resulting from trauma.
Discussion
The present study reports resolution of GERD symptoms 
after treatment with different dosages of esomeprazole 
and assesses the possible value of tailoring a PPI dosage to 
achieve heartburn relief/resolution in individual patients. 
In this study, esomeprazole was an effective treatment for 
heartburn in a selected patient population with symptomatic 
GERD based on history of heartburn and relief by antacids/
acid suppression therapy and a positive esophageal acid 
perfusion test result. Sustained heartburn resolution rates for 
esomeprazole ranged from 41% to 48%, and heartburn relief 
rates ranged from 52% to 59% at week 4.
To assess the effect of increasing esomeprazole dosage 
in patients with acid-induced GERD-associated heartburn, 
we attempted to enrich the population for study entry with 
possible responders to esomeprazole by requiring a history of 
relief with antacids and/or acid suppression therapy and a posi-
tive esophageal acid perfusion test result. We   hypothesized 
that these requirements would identify patients who were 
more likely to respond to acid suppression therapy, allowing 
us to determine better the effects of PPI dosage on symptom 
  control. However, rates of sustained response to   esomeprazole 
20 mg once daily and 40 mg once daily were similar to those 
reported in other esomeprazole   studies of similar design24,25 
that did not attempt to enrich the population.
Several reasons may explain why this enrichment tech-
nique failed in our study. First, as a result of selecting our 
patient population in this manner, we may have selected 
a highly responsive subpopulation of patients for whom 
variations in symptom response to different doses and timing 
frequency of PPIs may not be detectable. PPIs do not abolish 
acid secretion, so the remaining “weakly acidic” reflux epi-
sodes may continue to be effective in provoking heartburn or, 
alternatively, heartburn may be provoked by nonacidic com-
ponents in meals or refluxates in patients with symptomatic 
GERD. Additionally, although the esophageal acid perfusion 
test result has been reported by some investigators to have 
a good clinical correlation with a GERD diagnosis,7 a weak 
association has been observed between a positive esophageal 
acid perfusion test result and symptom index.27 Therefore, 
although the test may identify individuals whose heartburn 
may be induced by high degrees of intraesophageal acidity, 
it does not exclude individuals who experience spontaneous 
episodes of heartburn caused by weakly acidic or nonacidic 
refluxates. Furthermore, the positive esophageal acid perfu-
sion test result does not establish symptomatic responsiveness 
to acid suppressant therapy. In this regard, one limitation 
of this study is that pH monitoring was not performed to 
confirm pharmacodynamic variations in efficacy of differ-
ent esomeprazole dosages on suppressing gastric acidity or 
decreasing esophageal acid exposure. Also, in a previous 
study of patients with Barrett’s esophagus, esomeprazole 
treatment yielded significantly improved, dose-dependent 
suppression of intragastric acidity without comparable effect 
on esophageal pH values in patients.12
In the present study, selecting patients with a history of 
positive response to acid suppression therapy does not appear 
to have enriched the study population for an increased symp-
tomatic response with increased esomeprazole dosages based 
on comparisons with previously reported response rates in 
studies of patients whose heartburn had not been determined 
to be acid-related.24,25 However, a comparison of the present 
results with those of previous studies is limited because of 
differences in study designs and analysis methods. In addi-
tion, the highly stringent criteria for gauging success in the 
relatively short four-week treatment period may not have 
allowed therapeutic effect to be achieved fully in the large 
number of patients with nonerosive reflux disease in this 
study.19 A four-week treatment period may not sufficiently 
heal the potential underlying lesions in symptomatic GERD 
Table 3 number of patients (%) with most commonly reported 
adverse eventsa
Adverse  
event
Esomeprazole  
20 mg  
once daily 
(n = 122)
Esomeprazole  
40 mg  
once daily 
(n = 121)
Esomeprazole   
40 mg  
twice daily 
(n = 126)
Diarrhea 4 (3.3) 7 (5.8) 6 (4.8)
headache 4 (3.3) 5 (4.1) 6 (4.8)
nausea 3 (2.5) 4 (3.3) 1 (0.8)
Constipation 0 1 (0.8) 4 (3.2)
Fatigue 0 4 (3.3) 1 (0.8)
nasopharyngitis 2 (1.6) 2 (1.7) 0
Upper  
respiratory  
tract infection
3 (2.5) 0 1 (0.8)
Note: aEvents with a total frequency $1% across treatment groups. Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
123
Esomeprazole and heartburn resolution in GErD
(eg, dilated intercellular spaces),28,29 thereby limiting the 
rates of symptom resolution. Healing of dilated intracellular 
spaces, which parallels heartburn resolution, can take as long 
as 3–6 months of PPI therapy.28,29
Nocturnal heartburn is common in patients with 
heartburn and may negatively affect their ability to sleep 
well, potentially impacting daytime functioning.30 Studies 
suggest that PPIs improve sleep quality in patients with 
GERD-related sleep disturbance.31–34 In the present study, 
a numeric trend was seen toward improvement in nocturnal 
heartburn resolution with esomeprazole 40 mg twice daily 
versus esomeprazole 20 mg once daily and esomeprazole 
40 mg once daily, but this difference was not statistically 
significant. The study did not clarify whether patients on 
once-daily esomeprazole with persistent nocturnal heart-
burn may benefit from an increase to twice-daily esomepra-
zole or whether the   possible trend toward improvement may 
be due to the increase in dose or the effect of split dosing. 
Neither pH monitoring nor biopsies were performed in the 
present study. Therefore, other etiologies characterized 
by heartburn symptoms, such as eosinophilic esophagitis, 
were not addressed.3 Such etiologies may confound the 
responses observed during esophageal acid perfusion test-
ing. However, patients with a history of endoscopically 
verified erosive esophagitis within the last 16 weeks before 
randomization were excluded from the study unless healing 
had been documented.
Apart from a trend toward improved nocturnal heartburn 
resolution, this study did not support a dose response in the 
other endpoint measures, a finding reported in other studies 
of PPIs in patients who had symptomatic GERD.24,25,35–37 The 
present findings suggest that a plateau effect exists in terms 
of clinical response to acid suppression with PPI therapy 
with respect to day-long heartburn resolution. However, this 
result does not exclude the possibility of a dose or timing 
frequency response for nighttime heartburn.
Similar observations were made in studies investigating 
heartburn resolution in patients with erosive esophagitis.38,39 
In a study by Kahrilas et al,38 no differences were seen in 
heartburn resolution even though esomeprazole 40 mg was 
superior to omeprazole 20 mg for acid suppression. Specifi-
cally, esomeprazole at doses of 40 and 20 mg was superior to 
omeprazole 20 mg in achieving heartburn-free nights. Only 
the 40-mg dose of esomeprazole was superior to omeprazole 
in heartburn-free days. Moreover, these improvements in 
heartburn resolution were associated with improved healing.38 
Katz et al39 similarly demonstrated that greater intragastric 
acid control (ie, mean percentage of time with pH .4) with 
esomeprazole 40 mg once daily did not correlate with resolu-
tion of heartburn symptoms in patients with endoscopically 
verified erosive esophagitis. Increased intragastric acid con-
trol had a positive correlation with healing status of erosive 
esophagitis and with the severity of daytime and nighttime 
heartburn symptoms.39 However, no significant correlation 
was found between intragastric acid control and changes 
in symptom severity from baseline to the conclusion of the 
28-day study.39
Although results from the two previously described   studies 
were similar to those in the present study, the previous two 
study populations consisted of patients with erosive esophagitis, 
whereas the present study specifically excluded patients with 
erosive esophagitis. Therefore, the underlying mechanisms 
influencing response to therapy in these two patient populations 
may have differed from those seen in the present study. How-
ever, on the basis of the previous studies, symptoms do not 
appear to be sensitive to   modest changes in the degree of acid 
suppression achievable with PPIs. These results, along with 
findings of the present study, raise the question of whether 
an increase in PPI dose or modification in the timing of PPI 
administration can lead to clinical improvements in GERD 
symptoms, subject to possible clinical variations in different 
subpopulations of GERD patients. Additionally, these findings 
suggest the possibility that optimal symptom resolution in 
patients with GERD may require the management of other 
factors besides acid suppression.
In summary, the results of this study showed that four 
weeks of esomeprazole therapy achieved a reasonable rate of 
success in providing sustained heartburn resolution. Although 
the study failed to demonstrate a clinically significant effect 
after enrichment of the population based on history of relief 
by antacids/acid suppression therapy and esophageal acid 
perfusion testing, a numeric but nonsignificant trend toward 
improvement in nocturnal heartburn resolution with esome-
prazole 40 mg twice daily was observed. Additional research 
into the dose, timing of administration, and split-dosing 
regimens in different subpopulations of GERD patients is 
warranted to understand further the possible value of tailoring 
PPI dose and timing of administration to achieve clinically 
meaningful symptom improvements in the individual patient. 
However, a ceiling effect appears to exist for clinical response 
with acid suppression in the overall population of patients 
with GERD. Future areas of research may include dose titra-
tion studies in patients who are unresponsive to standard PPI 
doses and the identification and management of other disease 
components of GERD to optimize treatment in other selected 
subpopulations.Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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